

Listing of the claims:

1.-27. (Canceled).

28. (Withdrawn) A method of reducing viral load of a herpes infection in an interstitial space of a mammal, the method comprising:

identifying a mammal suspected of having been infected by a herpes virus in an interstitial space;

providing said mammal an amount of a pharmaceutical composition consisting essentially of beta-cyclodextrin; and

measuring the reduction of the viral load of herpes in the interstitial space of the mammal.

29.-30. (Canceled).

31. (Withdrawn) The method of claim 28, wherein the beta-cyclodextrin is 2-OH-propyl-beta-cyclodextrin.

32.-33. (Canceled).

34. (Original) The method of claim 28, further comprising administering to the mammal an amount of a cholesterol lowering agent effective to reduce the level of serum cholesterol in the mammal.

35. (Withdrawn) The method of claim 28, wherein the beta-cyclodextrin is provided intravenously.

36. (Withdrawn) The method of claim 35, wherein the beta-cyclodextrin is provided by a bolus injection.

37. (Withdrawn) The method of claim 35, wherein the beta-cyclodextrin is infused into the mammal over a period of at least two minutes.

38. (Withdrawn) The method of claim 37, wherein the beta-cyclodextrin is provided in at least two intravenous administrations separated by an interval of at least one hour.

39. (Withdrawn) The method of claim 37, wherein the beta-cyclodextrin is provided in at least four intravenous administrations separated by an interval of at least 12 hours.

40. (Withdrawn) The method of claim 28, wherein the beta-cyclodextrin is provided with at least one antiviral agent.

41. (Withdrawn) The method of claim 28, wherein the method comprises measuring the titer of the envelope virus after providing the beta-cyclodextrin.

42. (Withdrawn) The method of claim 28, wherein the method comprises measuring the titer of the envelope virus before providing the beta-cyclodextrin.

43. (Withdrawn) The method of claim 28, wherein the method comprises measuring an immune response in the mammal against the herpes virus after providing the beta-cyclodextrin.

44. (Withdrawn) The method of claim 28, wherein the method comprises measuring an immune response in the mammal against the herpes virus before providing the beta-cyclodextrin.

45.-48. (Canceled).

49. (Withdrawn) The method of claim 28, wherein the herpes virus is human herpes virus 1.

50. (Withdrawn) The method of claim 48, wherein the herpes virus is human herpes virus 2.

51. (Withdrawn) The method of claim 46, wherein the envelope virus is a poxvirus.

52. (Canceled).

53. (Withdrawn) The method of claim 28, wherein the beta-cyclodextrin is provided with at least one antiviral agent.

54. (Canceled).

55. (Withdrawn) The method of claim 54, wherein the microorganism is a bacterium.

56. (Withdrawn) The method of claim 54, wherein the microorganism is a mycobacterium.

57. (Canceled).

58. (Withdrawn) The method of claim 54, wherein the microorganism is a fungus.

59. (Withdrawn) The method of claim 54, wherein the microorganism is a protozoan.

60.-72. (Canceled).